Source: Annual Congress 2009 - New bronchodilators
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
A. Yorgancioglu, D. Mahler, A. Iqbal, R. Owen, M. Higgins, B. Kramer (Manisa, Turkey; New Hampshire, East Hanover, United States Of America; Horsham, United Kingdom). Indacaterol once-daily improves health-related quality of life in COPD patients: a 26-week comparison with placebo and tiotropium. Eur Respir J 2009; 34: Suppl. 53, 2028

Member's Comments

No comment yet.

Related content which might interest you: Indacaterol once-daily improves health-related quality of life (HRQOL) in COPD patients: a 52-week study Source: Annual Congress 2009 - New bronchodilators Year: 2009 A comparative trial of tiotropium, salmeterol and placebo: health-related quality of life Source: Eur Respir J 2001; 18: Suppl. 33, 26s Year: 2001 Indacaterol once-daily improves day and night-time symptom control in COPD patients: a 26-week study versus placebo and tiotropium Source: Annual Congress 2009 - New bronchodilators Year: 2009 NVA237 once daily improves dyspnea and health-related quality of life (HRQoL) in patients with COPD: The GLOW1 trial Source: Annual Congress 2011 - Bronchodilators in asthma and COPD Year: 2011 Tiotropium + olodaterol fixed-dose combination shows clinically meaningful improvements in quality of life versus placebo Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis Year: 2015 Indacaterol once-daily provides effective 24-h bronchodilation in COPD patients: a 26-week evaluation vs placebo and tiotropium Source: Annual Congress 2009 - New bronchodilators Year: 2009 Safety and tolerability of indacaterol once-daily in COPD patients versus placebo and tiotropium: a 26-week study Source: Annual Congress 2009 - New bronchodilators Year: 2009 Indacaterol once-daily improves dyspnoea in COPD patients: a 26-week placebo-controlled study with open-label tiotropium comparison Source: Annual Congress 2009 - Next generation bronchodilators Year: 2009 Health-related quality of life and asthma control in patients treated with budesonide and formoterol in a single inhaler Source: Eur Respir J 2001; 18: Suppl. 33, 46s Year: 2001 A placebo controlled trial with inhaled mannitol improves health related quality of life in patients with bronchiectasis Source: Annual Congress 2004 - Bronchiectasis Year: 2004 Once-daily QVA149 improves dyspnoea and health status compared with tiotropium plus formoterol in patients without ICS use: A post-hoc analysis of the QUANTIFY study Source: International Congress 2015 – New data on established treatments for asthma and COPD Year: 2015 Efficacy and safety of twice-daily aclidinium bromide compared with tiotropium and placebo in patients with moderate to severe COPD Source: Annual Congress 2010 - Regulation of airway hyperresponsiveness and bronchodilators Year: 2010 Patients with COPD using salmeterol/fluticasone propionate combination therapy experience improved quality of life Source: Eur Respir J 2003; 22: Suppl. 45, 51s Year: 2003 Bronchodilator therapy with indacaterol once-daily in COPD: a 52-week comparison with formoterol Source: Annual Congress 2009 - Next generation bronchodilators Year: 2009 Once-daily NVA237 reduces exacerbations and improves symptoms in COPD patients: A pooled analysis of the GLOW1 and GLOW2 studies Source: Annual Congress 2012 - Trials in COPD: novel treatments and insights Year: 2012 QVA149 is more efficacious than tiotropium and salmeterol/fluticasone combination (SFC) in improving patient-reported outcomes and lung function in COPD patients with moderate-to-severe baseline dyspnoea: The IGNITE trials Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis Year: 2015 ACCORD COPD I: Twice-daily aclidinium bromide improves quality of life and dyspnea in COPD patients Source: Annual Congress 2011 - Bronchodilators in asthma and COPD Year: 2011 Once-daily QVA149 provides the same efficacy as the free combination of its monocomponents indacaterol and glycopyrronium: The BEACON study Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs Year: 2013 Salmeterol/fluticasone (seretide, S/F) used as needed improves health-related quality of life in asthmatic adolescents uncontrolled with ICS receiving inhaled short-acting β2 agonists (SAB2A) Source: Eur Respir J 2004; 24: Suppl. 48, 380s Year: 2004 Indacaterol once-daily improves symptom control in COPD patients: a 52-week evaluation vs placebo (pbo) and formoterol (for) Source: Annual Congress 2009 - New bronchodilators Year: 2009